United Therapeutics Co. (NASDAQ:UTHR) Position Reduced by Fifth Third Wealth Advisors LLC

Fifth Third Wealth Advisors LLC reduced its position in United Therapeutics Co. (NASDAQ:UTHR) by 20.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,184 shares of the biotechnology company’s stock after selling 304 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in United Therapeutics were worth $418,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. American Century Companies Inc. grew its position in United Therapeutics by 42.8% during the 2nd quarter. American Century Companies Inc. now owns 41,233 shares of the biotechnology company’s stock worth $13,135,000 after purchasing an additional 12,360 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of United Therapeutics by 18.2% in the second quarter. Parallel Advisors LLC now owns 937 shares of the biotechnology company’s stock worth $298,000 after buying an additional 144 shares during the period. Envestnet Asset Management Inc. grew its holdings in shares of United Therapeutics by 12.7% during the second quarter. Envestnet Asset Management Inc. now owns 48,981 shares of the biotechnology company’s stock valued at $15,603,000 after buying an additional 5,531 shares in the last quarter. Dimensional Fund Advisors LP raised its position in United Therapeutics by 4.0% during the second quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock valued at $186,656,000 after buying an additional 22,683 shares during the period. Finally, Mercer Global Advisors Inc. ADV lifted its stake in United Therapeutics by 16.9% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 13,918 shares of the biotechnology company’s stock worth $4,433,000 after acquiring an additional 2,013 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In other news, Director Christopher Causey sold 510 shares of United Therapeutics stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the transaction, the director now directly owns 3,675 shares in the company, valued at approximately $1,384,115.25. The trade was a 12.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of the stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the sale, the director now owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 144,630 shares of company stock valued at $54,371,916. Company insiders own 11.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on UTHR. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Jefferies Financial Group boosted their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. The Goldman Sachs Group increased their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. TD Cowen boosted their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. Finally, LADENBURG THALM/SH SH upped their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $378.36.

United Therapeutics Price Performance

NASDAQ UTHR opened at $366.39 on Friday. The firm has a market cap of $16.36 billion, a P/E ratio of 16.09, a price-to-earnings-growth ratio of 0.93 and a beta of 0.57. The stock’s 50-day moving average is $369.14 and its two-hundred day moving average is $353.37. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same period in the previous year, the company earned $5.38 EPS. The company’s revenue for the quarter was up 22.9% on a year-over-year basis. On average, equities analysts expect that United Therapeutics Co. will post 25.22 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.